GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
GWPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
ICPTIntercept Pharmaceuticals, Inc.
-1.87%65.6022.0%$144.16m
ZGNXZogenix, Inc.
-4.15%38.1013.2%$133.37m
SHPGShire PLC Sponsored ADR
-0.32%144.780.4%$128.86m
VRXValeant Pharmaceuticals International, Inc.
-0.74%12.0414.2%$116.74m
PRGOPerrigo Co. Plc
-1.27%86.336.5%$92.37m
AERIAerie Pharmaceuticals, Inc.
-2.77%63.308.6%$60.54m
CTLTCatalent Inc
-0.51%42.742.7%$56.59m
MNKMallinckrodt Plc
-5.04%30.7917.7%$55.28m
JAZZJazz Pharmaceuticals Plc
-2.70%140.162.2%$53.67m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-2.37%105.087.6%$49.73m
UTHRUnited Therapeutics Corporation
0.18%121.2314.4%$45.48m
ENDPEndo International Plc
-3.11%7.488.9%$40.11m
PTLAPortola Pharmaceuticals, Inc.
-2.11%49.587.9%$36.19m
HZNPHorizon Pharma plc
-1.63%13.867.6%$34.20m
CORTCorcept Therapeutics Incorporated.
3.81%19.095.6%$32.52m

Company Profile

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development, and Pipeline Research & Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.